Joel Isaacson & Co. LLC bought a new stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 5,000 shares of the company's stock, valued at approximately $267,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC raised its position in shares of Doximity by 30.5% in the 3rd quarter. FMR LLC now owns 6,837,733 shares of the company's stock valued at $297,920,000 after buying an additional 1,598,602 shares in the last quarter. State Street Corp grew its holdings in shares of Doximity by 2.5% during the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company's stock valued at $160,947,000 after purchasing an additional 88,922 shares during the last quarter. Geode Capital Management LLC lifted its stake in Doximity by 19.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company's stock valued at $124,503,000 after purchasing an additional 472,565 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Doximity by 4.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 753,001 shares of the company's stock valued at $32,808,000 after purchasing an additional 31,966 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new position in Doximity in the 3rd quarter valued at approximately $29,453,000. 87.19% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts recently commented on DOCS shares. Stephens started coverage on shares of Doximity in a research note on Friday, December 20th. They issued an "equal weight" rating and a $55.00 price objective for the company. Mizuho increased their price objective on shares of Doximity from $55.00 to $65.00 and gave the company a "neutral" rating in a research note on Monday. Barclays upped their price target on shares of Doximity from $52.00 to $75.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. Wells Fargo & Company upped their price target on shares of Doximity from $43.00 to $55.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, Bank of America upped their price target on shares of Doximity from $54.00 to $57.00 and gave the company a "neutral" rating in a research report on Monday, January 6th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $64.22.
Check Out Our Latest Stock Report on DOCS
Insider Buying and Selling
In related news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the transaction, the director now directly owns 6,360 shares of the company's stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 37.40% of the stock is currently owned by insiders.
Doximity Price Performance
Shares of NASDAQ:DOCS traded up $0.11 during trading on Wednesday, hitting $75.05. The company's stock had a trading volume of 4,154,742 shares, compared to its average volume of 2,311,001. The company has a 50-day moving average of $56.61 and a 200-day moving average of $46.63. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $85.21. The firm has a market cap of $14.01 billion, a price-to-earnings ratio of 75.05, a P/E/G ratio of 4.61 and a beta of 1.39.
About Doximity
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Stories
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
